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Background: Up to 20% of cancers worldwide are thought to be associated with microbial pathogens, including
bacteria and viruses. The widely used methods of viral infection detection are usually limited to a few a priori
suspected viruses in one cancer type. To our knowledge, there have not been many broad screening approaches
to address this problem more comprehensively.
Methods: In this study, we performed a comprehensive screening for viruses in nine common cancers using a
multistep computational approach. Tumor transcriptome and genome sequencing data were available from The
Cancer Genome Atlas (TCGA). Nine hundred fifty eight primary tumors in nine common cancers with poor
prognosis were screened against a non-redundant database of virus sequences. DNA sequences from normal
matched tissue specimens were used as controls to test whether each virus is associated with tumors.
Results: We identified human papilloma virus type 18 (HPV-18) and four human herpes viruses (HHV) types 4, 5, 6B,
and 8, also known as EBV, CMV, roseola virus, and KSHV, in colon, rectal, and stomach adenocarcinomas. In total,
59% of screened gastrointestinal adenocarcinomas (GIA) were positive for at least one virus: 26% for EBV, 21% for
CMV, 7% for HHV-6B, and 20% for HPV-18. Over 20% of tumors were co-infected with multiple viruses. Two viruses
(EBV and CMV) were statistically significantly associated with colorectal cancers when compared to the matched
healthy tissues from the same individuals (p = 0.02 and 0.03, respectively). HPV-18 was not detected in DNA, and
thus, no association testing was possible. Nevertheless, HPV-18 expression patterns suggest viral integration in the
host genome, consistent with the potentially oncogenic nature of HPV-18 in colorectal adenocarcinomas. The
estimated counts of viral copies were below one per cell for all identified viruses and approached the detection limit.
Conclusions: Our comprehensive screening for viruses in multiple cancer types using next-generation sequencing data
clearly demonstrates the presence of viral sequences in GIA. EBV, CMV, and HPV-18 are potentially causal for GIA,
although their oncogenic role is yet to be established.
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Viruses may be more commonly associated with malignant
diseases than previously considered [1]. Reported associa-
tions do not always mean that a virus is a direct cause of
the cancer; they can be the result of contamination, viral
infection without causal involvement (‘passenger’), and
an indirect or direct causal relationship. Regardless of* Correspondence: dsalyakina@med.miami.edu
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the Creative Commons Attribution License (ht
distribution, and reproduction in any mediumthe causal relationship, viruses may have significant
clinical implications in human cancers through contri-
bution to dramatic changes in the microenvironment
and immunosurveillance.
The main strategies to detect and type various viruses
in cancers usually address individual protein biomarkers,
serological tests, or DNA/RNA detection of one or a few
viruses at a time. The major disadvantage of these strat-
egies is failure to detect viruses not previously known to
be associated with a particular cancer type. In this
report, we introduce a new and substantially differentMed Central Ltd. This is an open access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Sample size for available DNA and RNA






RNA DNA DNA DNA
AML, acute myeloid leukemia 123 nt nt nt
COAD, colon adenocarcinoma 194 77 56 16
KIRK, kidney renal clear carcinoma 132 nt nt nt
KIRP, kidney renal papillary cell
carcinoma
15 nt nt nt
LUAD, lung adenocarcinoma 58 nt nt nt
LUSK, lung squamous cell carcinoma 151 nt nt nt
READ, rectum adenocarcinoma 71 40 35 4
STAD, stomach adenocarcinoma 57 3 0 2
UCEC, uterine corpus endometrioid
carcinoma
157 nt nt nt
Control samples were derived from either whole blood or adjacent normal
tissue (not both) from the same patient. nt, not tested.
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sequencing (NGS) data to detect both human and non-
human nucleic acids in tumor specimens. This approach
does not require any prior knowledge of viruses involved
and can identify all known viral genomes. NGS provides
the opportunity to detect viral transcripts with high sensi-
tivity in the host tissue at frequencies less than 1 RNA mol-
ecule in 1 million [2]. Whole genome or transcriptome
tumor sequencing data provides a unique resource for the
development of new and powerful methodologies to detect
and characterize viruses in cancers.
‘Computational subtraction’ is the general concept for
detecting infectious agents in the host NGS material [3].
During this procedure, human and artifact sequences are
removed from the NGS data and the remaining se-
quences are aligned to bacterial or viral references from
existing databases. A few groups have implemented
computational subtraction procedures for this purpose
[4,5]. To date, NGS data was successfully used for virus
identification in human papilloma virus (HPV)-associ-
ated squamous cell carcinomas [6-9] and hepatitis B
virus (HBV)-mediated hepatocellular carcinomas [5],
while other cancer types and viruses largely remain out
of the picture.
In this study, we present a comprehensive screening
for viruses in NGS data of nine common cancers in
1,007 patients, using The Cancer Genome Atlas (TCGA)
data. TCGA is a joint project of the National Cancer In-
stitute (NCI) and the National Human Genome Re-
search Institute (NHGRI). The goal of the TCGA project
is to collect and systematically explore the entire spectrum
of genomic changes involved in more than 20 types of hu-
man cancers. Comprehensive genomic characterization
has been published for three out of nine cancers studied
so far (lung squamous cell carcinoma, colon, and rectum
adenocarcinoma) [10,11]. Colon and rectum adenocarcin-
oma were shown to belong to one cancer type based on
their molecular profiles. In addition to the screening for
viruses, we perform association analysis of identified vi-
ruses with tumor vs. paired non-malignant tissue from the
same patients in order to determine whether the presence
of a virus is significantly associated with tumors and not
the normal cell types.
Results and discussion
Screening for viruses
Screening for viruses is an essential step in the con-
tinuum of research that is expected to lead to new treat-
ment strategies in patients with virus-positive tumors. In
this study, we performed the systematic screening for
potentially oncogenic viruses in nine cancer types from
TCGA (Table 1), most of which were not previously
known to be associated with viruses or have controver-
sial reports in this regard [12,13]. After subtraction ofnon-viral sequences, unaligned fragments were used in
virus identification (Figure 1). Sequences of Epstein-Barr
virus (EBV), cytomegalovirus (CMV), roseola virus
(HHV-6B), Kaposi’s sarcoma-associated human virus
(KSHV), and human papilloma virus type 18 (HPV-18)
were identified in transcriptomes of three gastrointes-
tinal adenocarcinomas (GIA): stomach, rectum, and
colon adenocarcinomas (STAD, READ, and COAD, re-
spectively). In total, 83% of the viral reads mapped to
the known coding regions. The remaining six cancer
types (Table 1) were virus negative according to our
computational pipeline. Table 2 represents a summary
for the sequencing data in the GIA samples and matched
controls.
Viruses in gastrointestinal adenocarcinomas
EBV, CMV, and HHV-6B were detected in all three GIA,
while HPV-18 was detected in colorectal cancers only.
In total, 189 (58.7%) GIA samples were infected with at
least one virus: 83 (25.8%) with EBV, 67 (20.8%) with
CMV, 22 (6.8%) with HHV-6B, and 64 (19.8%) with
HPV-18 (Figure 2). One STAD RNA sample was KSHV
positive with 115 sequence reads mapping to 3,280 bases
of the viral genome (Additional file 1: Table S1). During
the review of this paper, another group published a very
similar study including 3,775 tumors from TCGA [14].
However, in their computational pipeline, Khoury with
colleagues did not detect any viral sequences in 138
COAD and 66 READ samples. In addition, they only re-
ported four EBV-positive samples in the STAD. Khoury
et al. used a different sequence aligner (MOSAIK) and
more stringent cutoff for the viral gene expression detec-
tion. Although no explicit cutoff is stated in the paper
Figure 1 Data analysis flowchart. Before step I, sequencing reads with phred-like quality scores q < 30 were removed. N in steps II, III, and IV
reflects the number of reference sequences from corresponding databases. For the alignment in steps II, III, and IV, we combined reference fasta
files into ‘supergenomes’ including vector sequences, bacterial genomes, and viral genomes, respectively. Each individual reference sequence in
the ‘supergenome’ was treated as a chromosome. All supergenome reference files were indexed before alignment steps.
Salyakina and Tsinoremas Human Genomics 2013, 7:23 Page 3 of 12
http://www.humgenomics.com/content/7/1/23[14], the VirusSeq pipeline [5] implemented in their
study uses 1,000 reads as a cutoff for virus detection. In
our case, the number of identified reads was far below
1,000 for all transcriptomes, except two EBV-positive
STAD tumors. The probable reason for using such a
high cutoff in VirusSeq pipeline is the high number of
false-positive results due to the homology of the con-
taminating vector and bacterial sequences. In our pipe-
line, adding steps II and III, in which these sequences
are subtracted, alleviates this problem, reducing the
number of unaligned RNA-seq reads by 19% on average
before aligning to the virus reference. In our experience,
these two steps are essential since they eliminate false-
positive findings and increase specificity of the method.
We included here 57 STAD samples, not 71 as in [14].
To our knowledge, 14 additional patients reported in
[14] have withdrawn their consent to participate in
TCGA study (as of November 1, 2012).
All viruses identified in GIA are ubiquitous in human
population. The first encounter with EBV, CMV, andHHV-6B infection usually happens in early childhood
and results in latent lifelong infection with a prevalence
of over 90% in adults [15-21]. Similarly, KSHV infects
7.2% and 49% of the population depending on the geo-
graphical region [22-24]. At the same time, HPV is the
most common sexually transmitted infection with a life-
long prevalence of 71%, although unlike herpes virus in-
fections, about 90% of HPV infection is cleared within 2
years without any consequences [25].
EBV, HPV-18, KSHV, and CMV have been linked to
multiple cancers and potentially are oncogenic in GIA.
EBV has been accepted as an infective agent of gastric
and colorectal carcinomas. Nearly 10% of all gastric can-
cers [26-30] and up to 30% of colorectal carcinomas
[31-35] have been found to be EBV-infected monoclonal
epithelial cells. In TCGA, 45.6% of STAD, 22.6% of
COAD, and 31% of READ samples were EBV positive
[36,37] (Figure 2). Multiple studies have also shown sig-
nificant association of high-risk HPV types with colorec-
tal cancers with infection rate of up to 84% [38-41]. The
Table 2 Total number of next-generation sequencing reads/fragments available for gastrointestinal cancers organized
by cancer and tissue type
Cohort Statistics Primary tumor Primary tumor Blood Solid tissue






COAD Min 5,244,743 60,872,080 0.47 64,637,478 0.50 148,341,394 1.18
Mean 26,127,635 205,217,167 1.63 182,959,915 1.45 224,838,391 1.77
Median 27,424,762 196,408,988 1.57 193,657,350 1.49 196,072,876 1.57
Max 64,021,517 1,162,469,344 9.43 354,790,740 2.85 429,443,164 3.36
READ Min 19,665,974 89,943,982 0.70 90,122,736 0.70 95,061,666 0.75
Mean 26,782,703 225,818,442 1.79 214,787,544 1.71 150,549,985 1.19
Median 27,121,702 227,226,239 1.81 224,045,358 1.80 159,027,517 1.26
Max 33,338,326 461,153,444 3.68 367,295,986 2.93 189,083,240 1.47
STAD Min 127,157,036 259,701,502 2.08 NA NA 418,702,808 3.34
Mean 155,138,810 300,668,630 2.40 NA NA 448,318,606 3.58
Median 155,490,548 280,015,346 2.23 NA NA 448,318,606 3.58
Max 193,445,130 362,289,042 2.88 NA NA 477,934,404 3.82
Paired reads are counted as two single fragments. COAD, colon adenocarcinoma; READ, rectum adenocarcinoma; STAD, stomach adenocarcinoma; NA, no data
available. aAverage coverage was calculated as the number of reads multiplied by the average read length (51 nt) and divided by the corresponding genome
length, divided by two for diploid genome.
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tially lower: 31% in COAD and 0.4% in READ. Differ-
ences in frequencies between previously reported and
our studies can result from multiple factors, such as
varying sensitivity of detection methods used as well as
population demographics. For instance, EBV positivity in
STAD has been reported to be higher in males, young
subjects, non-antral subsites, diffuse-type histology, and
in studies from the Americas [27]. Given the sample size
of the STAD cohort and the number of viruses, no epi-
demiological analyses were done. COAD and READ
combined provided a sufficient sample size for associ-
ation testing with clinical and demographic variables
(Additional file 1: Tables S2–S12). No association with
gender, age at initial diagnosis, histological type or ‘M’
and ‘N’ staging was found. Nominal p values are shown
in Table 3. After correction for multiple testing, the onlyFigure 2 Counts of tumors with viral co-infection. (A) In the COAD, (B)
positive when viral sequences were identified in the tumor transcriptome oassociation of HPV-18 infection with anatomic subdiv-
ision was statistically significant. HPV-18 was predomin-
antly associated with tumors located in the cecum and
ascending colon. No large epidemiological studies for
HPV-associated COAD are available thus far to compare
these results to.
CMV is also capable of transforming mammalian cells
through various pathways [42] and has been linked to
colorectal cancer, although available evidence is scarce
[43]. KSHV causes Kaposi’s sarcoma [44] and, to our
knowledge, has not yet been associated with gastric
adenocarcinomas. This may be a special case of STAD
that needs further investigation.
Co-infection with multiple viruses
A substantial proportion of GIA was co-infected with
multiple viruses: 46 (23%) COAD, 11 (19.3%) STAD, andin the READ, and (C) in the STAD. Tumors were considered virus
r genome.
Table 3 Nominal p values for association testing of virus
with clinical and demographic phenotypes
Phenotype HPV-18 EBV CMV HHV-6B
Gender 1.00 1.00 1.00 0.54
Age at initial diagnosis 0.22 0.51 0.07 0.26
Anatomic subdivision 5.0E − 05* 0.23 0.06 0.02
Histological type 0.39 0.52 0.82 0.55
History of colon polyps 3.0E − 03 0.77 0.22 0.83
Pathologic M 0.84 0.32 0.21 1.00
Pathologic N 0.59 0.11 0.58 0.13
Pathologic T 0.33 0.03 0.09 0.48
Stage 0.89 0.01 0.12 0.64
*p value is significant after Bonferroni correction at α = 0.05.
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co-infected. These multiple viruses may either co-exist
in the same cancer cells or populate different cell types
that compose or infiltrate the tumor. Szostek et al. sug-
gests that co-infection with HHVs, especially CMV and
EBV, may increase probability of the HPV-16 integration
into the host genome during cervical cancer tumorigen-
esis [45]. Similar mechanisms may be involved with EBV,
CMV, and HPV-18 in colorectal adenocarcinomas and
need to be tested in future studies. Alternatively, some
of the identified viruses can also preferentially infect
cancer cells, taking advantage of the impaired immune
environment of the tumors.
Virus quantification
The proportion of viral transcriptome reads relative to the
total number of reads in the GIA ranged from 6 × 10−9
(HHV-6B) to 2 × 10−5 (EBV). The majority of tumors
did not have a sufficient number of reads to cover
the whole viral genome or to allow transcript quantifica-
tion (see Additional file 1: Table S1 and Additional file 2).
The number of viral sequence reads detected in tumor
transcriptomes varied from a single fragment to tens of
thousands of fragments per sample, with a strong
skew towards low counts (Figure 3). Only five or less
viral sequence fragments were detected in 49% of the
transcriptomes and only one fragment in 21%. However,
our follow-up Basic Local Alignment Search Tool (BLAST)
analysis, described in the ‘Methods’ section, demonstrated
that even detection of a single short read may be sufficient
to ensure unambiguous viral detection, confirming high
specificity of sequencing alignment [8].
The estimated viral load for EBV, CMV, and HHV-6B in
GIA was less than one viral copy per cell (vc/c) in all cases
with a maximum of 0.72 vc/c (HHV-6B) (Additional file 1:
Table S1). The latter is equivalent to one viral genome per
1.39 human cells. This data supports the hypothesis that
only a small proportion of tumor cells had a virus. Theviral DNA abundance for EBV and CMV correlated with
the proportion of total viral RNA reads (Additional file 3).
Because no genomic data was available for KSHV-positive
tumor and no HPV-18 was detectable in genomic DNA
from tumors or normal cells, no viral load for these vi-
ruses could be calculated. The HPV-18 genome (7,857 nt
for RefSeq ID: NC_001357) is 20 to 30 times smaller than
the HHV (162,114–235,646 nt). The HPV-18 DNA quan-
tity must have been below the detection limit at the avail-
able sequencing depth. The lowest detection threshold for
NGS studies is limited to one sequence read aligning to
the target genome. As a result, the probability for detect-
ing a viral sequence in the host NGS data will be propor-
tional to the target sequence length, the viral load, and the
sequencing depth. Given the HPV-18 size and average
genome sequencing depth of GIA, the hypothetical aver-
age detection limit would be above 0.0047 vc/c (standard
deviation (SD) = 0.0023), equivalent to 1 virus in 261 hu-
man cells (SD = 133). This estimation does not take into
account possible data loss due to disproportional filtering
of highly polymorphic viral sequences through an un-
accepted number of mismatches and homopolymeric and
repetitive regions. Thus, the viral load is most likely
underestimated here. Currently, there is no clear consen-
sus on the minimum viral load indicative for the virus
causality in neoplasm. On one hand, viral genome abun-
dance and active expression of viral oncogenes are broadly
believed to indicate much greater viral involvement in dis-
ease than the silent presence of viral genome. On the
other hand, according to the ‘hit-and-run’ mechanism,
transient acquisition of viral genome may be sufficient to
induce malignant conversion [46]. In the hit-and-run sce-
nario, viruses may get partially or completely lost after
they cause permanent damage to the host cell and are no
longer necessary for the maintenance of the malignant
state. The most reliable estimates of viral load from the lit-
erature are related to HPV-associated tumors. The quanti-
tative PCR experiments report several HPV-18 copies per
cell [8,47]. However, Yoshida et al. suggested that very
early HPV-18 DNA integration may result in lower copy
numbers in cervical adenosquamous carcinoma (1.50–
0.89 vc/c), leading to a more aggressive transformation
with greater chromosomal instabilities, higher growth
rates, and rapid progression [47].
Virus association with tumors
Next, we tested if identified viruses were mostly found
in tumors compared to the non-malignant matched tis-
sue from the same individuals. One of the limitations of
this study is the absence of transcriptome data for
matched non-malignant tissues. Before association ana-
lysis, we explored if transcriptome and genome sequen-
cing data can be pooled for tumors and compared to
genomic data from non-malignant tissues. According to
Figure 3 Number of sequencing reads mapped to virus reference versus the total number of reads. The X-axis shows total RNA or DNA
fragments (short sequencing reads) in millions, and the Y-axis shows the number of fragments mapped to the particular virus, as stated in the
plot subtitles. Each data point represents one tumor. HPV-18 DNA was not detectable in the whole genome sequencing data. COAD are depicted
as read circles, READ as blue triangles, and STAD as black plus signs.
Salyakina and Tsinoremas Human Genomics 2013, 7:23 Page 6 of 12
http://www.humgenomics.com/content/7/1/23
Table 4 Counts of colorectal samples, positive (+) or
negative (−) for identified viruses, within tumor’s
DNA/RNA pairs
Sample type Virus name Tumor DNA
(N = 117)
CI for two one-sided
hypotheses (CL = 0.975)
Tumor RNA EBV + − 0; 3.09 0.40; infinity
+ 15 9
− 10 83
CMV + − 0; 0.51* 0.01; infinity
+ 13 13
− 1 90
HHV-6B + − 0; 18.84 0.85; infinity
+ 2 3
− 10 102
HPV-18 + − 0; 0.14* 0; infinity
+ 0 28
− 0 89
N, number of matched pairs. *proportions are not equivalent at α = 0.05 after
Bonferroni correction.
Table 5 Counts of colorectal samples, positive (+) or























EBV + − 0.02 0.06 1
+ 3 (3:0) 21 (19:2)
− 5 (5:0) 82 (64:18)
CMV + − 0.03 0.06 1
+ 0 12 (11:1)
− 1 (1:0) 98 (79:19)
HHV-6B + − 1 0.98 0.07
+ 4 (1:3) 8 (8:0)
− 10 (2:8) 89 (80:9)
HPV-18 + − - - -
+ 0 0
− 0 0
N, number of matched pairs. blood: solid, counts for the non-malignant sam-
ples by tissue type: whole blood and solid adjacent tissue, respectively.
Salyakina and Tsinoremas Human Genomics 2013, 7:23 Page 7 of 12
http://www.humgenomics.com/content/7/1/23our results, tumor DNA and RNA did not show statisti-
cally equivalent rates of virus positivity (Table 4). For
this reason, only DNA data from both tumors and non-
malignant matched controls were utilized for association
analysis. A sufficient number of whole genome sequen-
cing data was available for three viruses: EBV, CMV, and
HHV-6B in COAD and READ only. Since COAD and
READ are genetically identical [11], we combined the
two into colorectal adenocarcinomas (CRAD) to achieve
a higher sample size for association analysis. Our results
indicate that EBV and CMV were significantly associated
with CRAD vs. matched non-malignant specimens with
p = 0.0022 (pcorrected = 0.02) and p = 0.0034 (pcorrected
=0.03), respectively (Table 5). Since testing was done in
three tissue types: solid tumor, solid non-malignant adja-
cent tissue, and whole blood, these associations may re-
flect tissue-specific infection. Thus, we investigated if
viral rates differ between tissue types in controls. All
controls positive for EBV and CMV were blood samples,
and none of the tested solid tissue controls had these
two viruses (Table 5). In contrary, HHV-6B was identi-
fied predominantly (80%) in solid non-malignant tissue
and not blood, although association was not significant
after correction for multiple testing (pcorrected = 0.07).
These findings may reflect the fact that EBV and CMV
are associated with tumors, while HHV-6B is associated
with the colorectal tissue. EBV, CMV, and HPV-18 are
capable to infect different types of skin cells, endothe-
lium, or mucus membranes and are plausible infections
in the histological context of GIA. While the oncogenic
nature of CMV is still debatable [42], EBV and HPV-18
are potentially causal in GIA because both viruses en-
code oncoproteins, which are able to transform human
cells [30,39,48]. HHV-6B is known to propagate prefer-
entially in T lymphocytes or glial cells [49] and does not
have any known oncogenes. The presence of HHV-6B in
the colon and rectum may possibly originate from tissue
infiltration by infected lymphocytes, although this hy-
pothesis needs to be verified. One of the limitations of
our study is the lack of availability of corresponding
samples for further validation.
Virus integration into the human genome
Since no viral DNA for HPV-18 was identifiable, detec-
tion of integration sites of HPV-18 into the human gen-
ome was not possible. Nevertheless, the cumulative
expression pattern of HPV-18 in CRAD supports evi-
dence for genomic integration. The HPV episome usu-
ally becomes integrated into the host cell DNA during
oncogenesis by opening the ring molecule and disrupt-
ing the E2 gene, which normally suppresses oncogenes
E6 and E7. As a result, part of E2 and L2 and whole E4
and E5 genes become deleted. Expression of E6 and E7
downregulates p53 and pRb and promotes malignancy[50]. While three early viral genes, E1, E6, and E7,
showed high ‘cumulative expression levels’ in CRAD,
partial expression of E2 and whole L2, E4 and E5 was
not detected (Figure 4). Lack of expression in presum-
ably deleted regions suggests the potentially oncogenic
Figure 4 Circos plot for HPV-18 RNA-seq. From outside to the inside of the circle: (1) HPV-18 genomic positions; (2) number of sequencing
reads mapped to the viral genome in 64 colon and rectum adenocarcinomas combined. Range from 1 to 10 shown on light yellow background
as a black line, and from 11 to 61 on light green background as a green line; (3) viral genes mapped to genomic positions. While expression of
genes E6, E7, and E1 is obvious, genes L2, E5, E4, and part of E2 were not detected. This pattern is expected when HPV-18 integrates in the host
genome and part of the viral genome becomes deleted.
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poral relationship between infection and tumorigenesis
cannot be disseminated from this data. To conclusively
prove a causal role of viruses in cancer, a complete chain
of evidence from epidemiology, histopathology, and mo-
lecular biology is required.
For the remaining viruses detected in available gen-
omic data, the number of identified reads was not
sufficient for integration site detection (see Figure 3
and Additional file 2). Neither viral nor human ge-
nomes were covered without substantial gaps. As
shown in Table 2, the median coverage of the human
genome in colorectal samples was below 2x, and a
great majority of the viruses with available whole gen-
ome seq data had a small fraction of the genomes
covered.
Conclusions
Our results clearly demonstrate the presence of viral
sequences in GIA. EBV and CMV were statistically sig-
nificantly associated with CRAD. In addition, the expres-
sion pattern of HPV-18 was consistent with genomic
integration typical during oncogenesis [50]. This supportsthe hypothesis that EBV, CMV, and HPV-18 are potentially
oncogenic in GIA, although we realize that further
studies are needed before a conclusion can be made
about the pathophysiological role of the identified viruses
in GIA. No viruses were identified in the remaining six
cancer types.
Our results demonstrate the feasibility of NGS for the
identification of viruses at very low levels in the human
tissue. Unlike PCR-based approach, NGS data offer a
unique opportunity to capture any viral nucleic acids
present in the sample above the detection limit. Identifi-
cation of viral infection is a first step in determining the
role of viruses in cancer. Availability of comprehensive
viral databases makes it possible to scan for a large num-
ber of candidates without the need for de novo assembly
with the restriction that novel viruses will not be
detected.
Finally, in this study, we established an empirical de-
tection limit in our computational pipeline. This infor-
mation can be used to calculate the required sequencing
depth, as well as the amount of material needed by the
given size of viral genome, and the expected viral load in
similar studies.
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Subjects
Whole transcriptome sequencing data for nine cancer
types, comprising 1,007 patients, were obtained through
TCGA (accessed on October 17, 2011). Table 1 summa-
rizes specimen counts and abbreviations for the nine in-
cluded cancer types. Additional transcriptome and whole
genome sequencing data for three GIA were downloaded
on November 1, 2012. Sequencing has been done using
Illumina (Solexa, GAII, Illumina, Inc., San Diego, CA,
USA) or SOLiD™ technology (Life Technologies, Carlsbad,
CA, USA). A detailed description of the TCGA data
can be found on the following TCGA websites: http://
cancergenome.nih.gov/, https://tcga-data.nci.nih.gov/tcga/,
as well as in two recently published studies on genomic
characterization of three out of nine cancer types dis-
cussed here [10,11]. Patient enrollment and utilization
of data were conducted in accordance with TCGA




Cancers selected for the TCGA study were chosen
based on specific criteria that included (1) poor progno-
sis and high public health impact, and (2) availability of
human tumor and matched normal tissue that meet
TCGA standards for patient consent, quality, and quan-
tity. The proportion of 60% tumor nuclei in the speci-
mens was found to be sufficient by TCGA project
organizers to generate high-quality data, in which the tu-
mor’s signal can be distinguished from other cells’ signals
when using NGS. Only primary, untreated tumors were
collected. Samples were frozen quickly after surgery in
order to prevent degradation of the RNA and DNA.
Whole genome sequencing data was available for
37.5% of the GIA (Table 1). Blood or germ line speci-
mens derived from the same individual as the tumor
specimens were used in the TCGA study to serve as
paired normal controls when available (Table 1). DNA
sequencing data from the blood or adjacent healthy tis-
sue was available for 35% of the GIA specimens.
Bioinformatics analysis
Transcriptome data (BAM files) generated by TCGA for
a total of 1,007 cancer specimens were analyzed in an
automated fashion on a computational cluster hosted by
the High-Performance Computing core at the Center for
Computational Science, University of Miami (http://ccs.
miami.edu/). An IBM BladeCenter cluster was available
for compute-intensive data analysis. The cluster, named
Pegasus running under Linux operation system, was
used consisting of 280 computing nodes each with 8
Xeon 2.6 GHz cores and 16 GB of memory, and 700
computing nodes each with 4 Opteron 2.2 GHz coreand 4 GB of memory. These nodes are interconnected
by Gigabit Ethernet and feature a 21 TB NFS file system
providing an aggregate of 5,040 cores and 7.3 TB of
memory. All computational tasks were submitted in
parallel to the LSF job scheduler and resource manage-
ment system. The computational pipeline is outlined in
Figure 1. In total, 1,156 jobs were submitted to the
cluster for steps I–V for DNA-seq and RNA-seq data;
25,245 CPU hours were used for data analysis.
Bamtools-1.0.2 [51] and samtools-0.1.18 [52] software
were employed for converting data format. Sequencing
reads with phred-like quality scores q > 30 were utilized.
TopHat (v.2.0.0) [53] was consistently used for all tran-
scriptome mapping steps. Multiple threads were used
during alignment with option –p 8. When subtracting
bacterial and viral sequences, we allowed TopHat to
tolerate up to four mismatches per read, instead of the
default of two in the alignment step, to allow for poten-
tially higher mismatch rates due to mutations [54] or
imperfect match to the reference sequence. In addition,
TopHat was instructed to use a .gtf file and not to look
for novel transcript junctions by utilizing the ‘—no-
novel-junc’ flag. We combined reference fasta files into
‘supergenomes’ for vector sequences, bacterial genomes,
and viral genomes for steps II, III, and IV, respectively
(Figure 1). Each individual reference sequence in the
‘supergenome’ was treated as a chromosome. Reference
files were indexed before alignment steps. The bacterial
reference file had to be split into two parts to reduce the
memory use needed for indexing and mapping steps. Even
the single short read aligning to the viral reference was
considered as successful detection, if following BLAST
analysis [55] versus the NCBI nucleotide (nt) collection
confirmed sequence similarity with the target over 98%
and at least one transcriptome out of a cohort had more
than 10 reads mapped to a viral genome reference. Se-
quences aligning to multiple organisms, known artificial
(vector) sequences, or low-complexity sequences were
considered false positive and removed.
Only three gastrointestinal cancer types, stomach
(STAD), rectum (READ), and colon adenocarcinomas
(COAD), which tested virus positive on the transcrip-
tome level, proceeded to the whole genome analysis step
(Table 1). Burrows-Wheeler Aligner (BWA, v.0.5.9) [56]
with default options was consistently used for genomic
data alignment. Multiple threads were used when run-
ning BWA with option –t 4. Genomic read subtraction
was performed in exactly the same fashion as described
above for transcriptomes (Figure 1). In order to deter-
mine computational pipeline sensitivity to single nucleo-
tide mismatches, sequence reads on EBV and HPV-18
with different mutation/mismatch rates and lengths were
simulated and run through the computational subtrac-
tion and alignment steps (see Additional files 1 and 4).
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EBV reference genomes include two very similar strains
HHV-4.1 (NC_007605) and HHV-4.2 (NC_009334). In
order to capture as many reads as possible, we created
a consensus sequence using both NC_007605 and
NC_009334 genome references. We replaced the two
original references for two strains with the consensus
reference for computational pipeline.
Statistical analysis
Since available data comprised cases-only DNA/RNA
and malignant/normal tissue pairs, a simple McNemar
test implemented in R library ‘exact2x2’ (v1.1-1.0) was
used for both equivalence and association testing [57].
Equivalence testing for virus identification in DNA and
RNA was performed using two one-sided exact McNe-
mar tests with a confidence level of 0.975 at α = 0.05
(Bonferroni-corrected for four viruses). The null hypoth-
esis of equivalence was rejected, when at least in one of
the one-sided tests, the confidence interval (CI) did not
include ‘1’. Association of virus with tumor vs. normal
tissue was done with two-sided exact McNemar test.
Since COAD and READ are genetically identical [11],
we combined two cohorts for association analysis to
achieve a higher sample size. Association testing of virus
presence in tumor/normal tissue was done using blood
and solid tissue controls in separate tests, as well as
blood and solid combined. Bonferroni correction was
done for nine tests (three types of control groups multi-
plied by three viruses identified in the whole genome
data). Fisher exact test was used for association testing
with clinicopathological and demographics variables.
Age at initial diagnosis in virus-positive and virus-
negative groups was compared using ANOVA. Bonfer-
roni correction was applied.
Estimation of viral load
We calculated V, the number of viral copies per cell
(vc/c), i.e., viral load, for each DNA sample as
V ¼ CV=CH;
where CV is the average sequencing coverage for the
virus, and CH is the average human genome coverage.
Average coverage C was calculated as
Ci ¼ Ri  L=Gi;
where i is the species, R is the number of reads, L = 51
and is the average read length in nucleotides, and G is
the corresponding genome length in nucleotides. For
the diploid human genome, C = CH/2.Additional files
Additional file 1: Simulations and viral rate estimations.
A document containing simulation methods and results, and
supplementary Tables 1–12, showing summary on viral reads detected,
as well as clinical and demographic data in gastrointestinal
adenocarcinomas.
Additional file 2: Dot matrix. This dot matrix view shows regions of
similarity based upon the BLASTN 2.2.27+ results. The viral genome
positions are on the X-axis. The lines represent mapped reads. The Y-axis
shows cumulative bases of the aligned reads over all GIA sorted by the
percentage of the genome covered. Higher coverage yields longer lines
on the plot. Viral RNA transcriptome reads, when mapped to their
reference genome sequences, showed uneven distribution clustering
most likely corresponding to actively transcribed genes. Genomic reads,
as expected, mapped along the viral reference genome randomly and
more uniformly than transcriptomic reads.
Additional file 3: Correlation of EBV and CMV load in tumor’s
transcriptomes and genomes. Each data point represents one
tumor. The X-axis shows log10-transformed percentage of viral reads in
tumor’s transcriptome; the Y-axis shows log10-transformed viral load
(nc/c, see methods) in tumor’s whole genome. COAD are depicted as
read circles, READ as blue triangles. STAD is not shown because there
was not a sufficient number of tumor genomes sequenced.
Additional file 4: Simulation results. At the low mutation rate up to
2%, derived reads were not lost to any significant extent, and our
pipeline still captured over 94% simulated reads by BWA (whole genome
pipeline) and over 80% by Tophat v.2.0.0 (transcriptome pipeline). Our
approach had highest sensitivity with the shortest reads (50 nt), being at
least 80% for BWA at a mismatch rate of 0.04, and 0.05 for Tophat. Higher
mutation rates greatly impacted sensitivity, especially for the longer
sequence reads, consistent with the BWA and TopHat algorithms. TopHat
used the bowtie2 aligner, which seems to be affected to a greater extent
by the length of the reads, probably due to using a fixed number of
mismatches (N = 4), while BWA allows a floating error rate k depending
on the read length. Simulated errors were randomly distributed. The
longer the read, the more likely was the inclusion of mismatches.
Subtraction of non-viral reads did not affect HPV-18 alignment, and less
than 1% of CMV reads were lost through this process at zero mutation
rate. As expected, computational subtraction eliminates individual viral
sequences to various extents, depending on the degree of homology
with non-viral reference sequences included in the filters.
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